BioForce Nanosciences (BFNH) Stock Price, News & Analysis

Company Overview

BioForce Nanosciences is a nanotechnology company that developed instrumentation, consumables and related technologies for life sciences research and nanoscale surface engineering. Its products were designed to help researchers manipulate very small volumes of liquids and create controlled patterns of biological or chemical materials on surfaces.

The company’s best-known technology was the Nano eNabler platform, also described as a molecular printer. The system used specialized dispensing tools to deposit precise quantities of fluids, enabling applications such as biomolecular patterning, microarray fabrication, cell-based research and other laboratory experiments involving nanoscale structures.

BioForce Nanosciences served research institutions, biotechnology companies and other organizations working in nanotechnology and the life sciences. Publicly available information about the company’s current operations, geographic reach and leadership is limited, and its present business status is unclear.

Key Stats

• Today's Range: $8.83 to $9.35
• 50-Day Range: $1.20 to $10.01
• 52-Week Range: $0.18 to $10.99
• Volume: 431 shs
• Average Volume: 17,757 shs
• Market Capitalization: $355.86 million
• P/E Ratio: 935.69
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioForce Nanosciences Stock Analysis - MarketRank™

BioForce Nanosciences scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioForce Nanosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioForce Nanosciences is 935.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioForce Nanosciences is 935.69, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.41.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of BioForce Nanosciences has been sold short.

Short Interest Ratio / Days to Cover

BioForce Nanosciences has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioForce Nanosciences has recently increased by 769.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioForce Nanosciences does not currently pay a dividend.

Dividend Growth

BioForce Nanosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

BioForce Nanosciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioForce Nanosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioForce Nanosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.54% of the stock of BioForce Nanosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioForce Nanosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BFNH
• CIK: 1310488
• Web: www.bioforceeclipse.com
• Phone: (757) 306-6090
• Fax: 757-306-6092
• Employees: 3
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 935.69
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.67%
• Return on Assets: -16.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.41
• Quick Ratio: 25.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -467.38

Miscellaneous

• Outstanding Shares: 38,070,000
• Free Float: 23,015,000
• Market Cap: $355.86 million
• Optionable: Not Optionable
• Beta: -0.31